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AP-1: Activating Protein 1  
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CpGs: Cytosine-phosphate-Guanine (CpG) sites 
DNA: deoxyribonucleic acid 
COPD: Chronic Obstructive Pulmonary Disease 
EWAS: Epigenome-Wide Association Study 
FDR: False Discovery Rate  
QQ plot: Quantile-Quantile plot 
To the Editor,  
 
Asthma is a chronic heterogeneous inflammatory airway disease. Its treatment includes 
bronchodilators and anti-inflammatory medication such as corticosteroids. Corticosteroids reduce 
transcription of AP-1 and NF-B and hence may affect DNA methylation. Epigenetics refers to 
changes in DNA that can affect transcription, such as methylation of a cytosine nucleotide beside a 
guanine nucleotide (CpGs). 
 
Asthma is associated with differentially methylated CpGs in specific genes [1, 2]. In the largest study 
to date, asthmatic children had significantly lower blood methylation levels at 14 CpGs compared to 
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controls [3]. One previous study found 19 CpGs that were differentially methylated in blood during 
systemic corticosteroid exposure in patients with COPD [4]. Possible effects of inhaled asthma 
medication on peripheral blood methylation profiles are currently unknown.  
 
Our aim was to study the association between inhaled corticosteroids and DNA methylation in 
peripheral blood cells in children with asthma. First, we performed an epigenome-wide association 
study (EWAS) investigating the effects of variable inhaled corticosteroid exposure on DNA 
methylation in 8-year-olds with diagnosed asthma in the BAMSE (Barn/Child, Allergy, Milieu, 
Stockholm, Epidemiology) cohort followed by replication attempts. Second, using a candidate gene 
approach, we evaluated if identified CpGs from the systemic steroid study [4] and the largest asthma 
study to date [3], in total 33 CpGs, were differentially methylated in relation to inhaled asthma 
treatment.  
 
BAMSE is a Swedish prospective birth cohort study [5]. A total of 4089 children born 1994-1996 
enrolled and information was collected in repeated questionnaires. Blood samples were taken at the 
8- and 16-year follow-ups (n=2480; 61 % and n=2547; 62 %, respectively) [6]. For the present study, 
we included all subjects with a doctor’s diagnosis of asthma ever up to 8 years and with DNA 
methylation data available for analyses (n=215) [3]. Subjects were grouped based on exposure 
established in the questionnaires: any medication for breathing difficulties (n=130), any inhaled 
corticosteroids or combination medication for any period of time (n=107), and inhaled 
corticosteroids continuously (at least 2 consecutive months) (n=39), all in the last 12 months. 
STOPPA (Swedish Twin Study on Prediction and Prevention of Asthma), a cohort study of twins aged 
9-14 years [7] was used for replication analyses, and a subset of BAMSE 16-year cohort (n=96 cases) 
was used for additional look-up (Tables E1-2). The regional ethics committee in Stockholm approved 
the studies, and written consent was obtained from all parents.  
             
Robust linear regression was used for the analysis. The reference group comprised subjects 
diagnosed with asthma without any asthma medication in the last 12 months (n=85). We applied the 
Benjamini-Hochberg method to control the false discovery rate (FDR) at 5 %. P values below FDR 
were considered statistically significant in EWAS. Analyses were performed separately in BAMSE and 
STOPPA followed by fixed-effects meta-analysis using METAL.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Beta value was a dependent variable and each mode of asthma medication was a binary 
independent variable. Each model was adjusted for sex, age, sensitization to airborne allergens at 8 
years, wheezing in the last 12 months, mother’s smoking at least 1 cigarette per day at baseline 
and/or during pregnancy, bisulfite treatment date, and estimated cell types according to the 
Houseman method [6] (Table 1). Similar subject groupings and identical models were applied in 
STOPPA and BAMSE 16-year analyses.  
 
Table 1. Distribution of background characteristics of BAMSE subjects with DNA methylation data 
measured at 8 years of age in relation to type of asthma treatment. Results shown as n (%), 
compared to the total number of subjects in each group. 
 Diagnosed asthma 
(n=215) 
Asthma treatment 
  Any medication for 
diagnosed asthma 
(n=130) 
Any inhaled 
corticosteroid 
treatment (n=107) 
Continuous inhaled 
corticosteroid 
treatment (n=39) 
Male 134 (62 %) 83 (64 %) 68 (64 %) 28 (72 %) 
Age in years (mean, SD) 8.1, 0.4 8.1, 0.4 8.1, 0.4 8.1, 0.4 
Sensitization
† 106 (49 %) 79 (61 %) 66 (62 %) 28 (72 %) 
At least 1 episode of 
wheezing in the past 12 
months 
104 (48 %) 96 (74 %) 83 (78 %) 31 (79 %) 
Either parent smoked at 
the time of the 8-year 
questionnaire 
46 (21 %) 22 (17 %) 20 (19 %) 6 (15 %) 
Mother's smoking
‡ 34 (16 %) 14 (11 %) 12 (11 %) 3 (8 %) 
Socioeconomic status at 
baseline, § blue collar 
worker compared to white 
collar worker  
35  
(16 %) 
180 
(84 %) 
23 
(18 %) 
107 
(82 %) 
20 
(19 %) 
87 
(81 %) 
9 
(23 %) 
30 
(77 %) 
One or both parents' 
asthma/hay fever/ allergy
¶ 
101 (47 %) 65 (50 %) 55 (51 %) 21 (54 %) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
† Sensitization is defined as an IgE antibody level of 0.35 kUA/L or greater against any inhalant allergen at age 
8.  
‡ The child’s mother smoked at least 1 cigarette per day at any point of time during the pregnancy and/or at 
the time of questionnaire 0 (median age of 2 months). 
§Socioeconomic status for the household at the time of questionnaire 0, according to dominance order in two 
classes. 
¶ Mother and/or father with doctor’s diagnosis of asthma and asthma medication and/or doctor’s diagnosis of 
hay fever in combination with furred pets- and/or pollen allergy at the time of questionnaire 0. 
 
In total, methylation at 24 individual CpGs was significantly associated at FDR level with asthma 
treatment in BAMSE (Table 2; Figures E1-3). However, none of these EWAS hits was nominally 
significant in the replication study STOPPA or in BAMSE 16-year-olds, and in the meta-analysis, none 
of the CpGs reached genome-wide significance (FDR). As a sensitivity analysis, we repeated 
regression analyses in BAMSE 8-year-olds, not adjusting for cell types, and found overall very 
consistent results comparing the regression coefficients in the models with and without cell type 
adjustment (Table 2).  
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Table 2. Statistically significant CpGs (defined as p value below respective FDR) from epigenome-
wide association study analyses of any asthma medication, any corticosteroid medication, and 
continuous corticosteroid medication exposure in the last 12 months and DNA methylation change 
in peripheral blood cells from Swedish 8-year-olds. Total sum of subjects included in each group is 
stated after the exposure type (n). FDR for all is 2,2E-06. “-“indicates missing value as these CpGs 
were not included in the STOPPA DNA methylation data after normalization. See appendix for further 
description.  
 
CpG site Gene
† 
 
Distance 
(bp) ‡ 
 
Coefficient, 
BAMSE 8
§ 
 
p value, 
BAMSE 8 
p value, 
STOPPA 
p value, 
Meta 
analysis* 
 
p value, 
BAMSE 
16 
Coefficient
BAMSE 8: 
no cell 
adjustmen
t
¶
 
p value, 
BAMSE 8: 
no cell 
adjustmen
t 
Any asthma medication exposure, n=130 
cg25214924 
AK0581
77 
-42380 -0.016 2.5E-08 0.29 2.6E-03 0.62 -0.013 1.0E-05 
cg03877376 TBX5 85 0.008 2.0E-07 - - 0.64 0.007 7.3E-06 
cg20423602 
ADARB
2-AS1 
-8232 -0.014 5.5E-07 0.13 1.5E-06 0.21 -0.012 1.2E-05 
cg15954046 LMNA 303 -0.012 5.5E-07 0.60 1.9E-04 0.51 -0.006 6.8E-02 
cg23966329 
UBE2G
1 
-162 -0.003 1.3E-06 0.34 7.4E-03 0.89 -0.003 1.1E-06 
cg14063914 SERAC1 349 -0.007 1.7E-06 0.45 4.3E-04 0.72 -0.008 7.3E-08 
cg21731304 
NMNA
T3 
-212 -0.021 2.0E-06 0.49 3.3E-05 0.15 -0.021 4.3E-06 
Any corticosteroid exposure, n=107 
cg16048421 
LOC338
579 
0 0.014 3.9E-07 0.80 7.2E-04 0.29 0,015 7,2E-07 
cg15115986 
C1orf1
12 
-20 -0.004 4.9E-07 - - 0.48 -0,004 2,7E-07 
cg03877376 TBX5 85 0.008 5.5E-07 - - 0.68 0,007 1,2E-05 
cg03146079 ADD1 0 -0.005 5.9E-07 0.32 1.6E-06 0.99 -0,005 7,4E-07 
cg17629264 MAPK8 -390 -0.021 6.1E-07 0.34 1.5E-05 0.18 -0,014 4,3E-03 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
IP2 
cg24144651 
BC0432
27 
-560 -0.009 8.8E-07 - - 0.18 -0,006 2,8E-03 
cg00025044 ERCC6 -1952 -0.011 1.0E-06 0.19 3.7E-05 0.42 -0,015 1,2E-08 
cg25745861 
TMEM
54 
-2782 0.012 1.1E-06 0.46 1.5E-05 0.85 0,016 5,8E-08 
cg14136328 SYT1 -69884 -0.013 1.1E-06 0.32 1.4E-03 0.43 -0,010 5,8E-05 
cg18046087 KLC2 0 -0.006 1.1E-06 0.76 4.9E-05 0.87 -0,007 3,9E-08 
cg03043078 
MMP1
7 
2420 -0.006 2.0E-06 0.99 4.0E-05 0.23 -0,006 1,3E-06 
Continuous corticosteroid exposure, n=39 
cg07665222 ACRV1 -1393 -0.022 3.3E-07 0.28 3.8E-06 0.75 -0,018 2,3E-04 
cg03877376 TBX5 85 0.010 9.4E-07 - - 0.94 0,009 2,2E-05 
cg22997262 
LOC100
128531 
-2329 0.017 1.1E-06 0.43 9.5E-03 0.54 0,018 9,2E-09 
cg15074789 EPHA2 0 -0.008 1.2E-06 - - 0.96 -0,008 9,4E-06 
cg13688889 FOXE1 -6829 -0.048 1.4E-06 0.72 3.1E-04 0.20 -0,049 1,6E-06 
cg00947413 
MIR367
9 
-99303 -0.044 1.8E-06 0.22 1.4E-05 0.26 -0,046 1,0E-07 
cg26281051 
DEFB12
9 
-95 -0.018 2.0E-06 0.46 2.9E-04 0.30 -0,017 1,3E-04 
cg25745861 
TMEM
54 
-2782 0.016 2.6E-06 0.71 1.4E-03 0.54 0,018 9,8E-06 
cg13492223 FUT6 -159 0.017 2.9E-06 0.81 6.0E-04 0.98 0,019 4,6E-04 
†, ‡
 
Gene annotation according to Illumina450K. CpGs were annotated using the 
IlluminaHumanMethylation450k.db R package, with enhanced annotation for nearest genes within 10Mb of 
each site, as previously described [8]. 
§ Regression coefficient, adjusted for sex, age, sensitization to airborne allergens at 8 years, wheezing in the 
last 12 months, mother’s smoking at least 1 cigarette per day at baseline and/or during pregnancy, bisulfite 
treatment date, and estimated cell types. Reference group includes subjects without any asthma medication.  
*Meta-analysis of results in BAMSE 8-year-old cohort and STOPPA using a fixed-effects model weighted by the 
inverse of the variance using METAL. BAMSE 16-year-olds were not included in the meta-analysis due to 
overlap with BAMSE 8 data. 
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¶ Regression coefficient, adjusted for sex, age, sensitization to airborne allergens at 8 years, wheezing in the 
last 12 months, mother’s smoking at least 1 cigarette per day at baseline and/or during pregnancy, and 
bisulfite treatment date. Reference group includes subjects without any asthma medication. 
 
Next, we investigated possible DNA methylation changes in the 33 selected CpGs from the literature 
[3], [4]. Three CpGs were nominally significant in BAMSE 8-year-olds when comparing any 
corticosteroid exposure to no medication and six CpGs showed nominally significant methylation 
increases in relation to continuous corticosteroid exposure with three CpGs increasing ≥1%. 
However, none of the CpGs survived multiple testing adjustment (Tables E3-5). We investigated the 
33 candidate CpGs in a subset of BAMSE 16-year-olds with an asthma diagnosis through identical 
analyses and congruently found no FDR-significant associations with asthma treatment.  
 
In summary, several CpGs in EWAS were found differentially methylated in BAMSE at the FDR 
genome-wide significance level and results were very similar in models with and without cell-type 
adjustment. However, none of these CpGs replicated even at a nominal significance level in STOPPA 
or BAMSE 16-year cohort, and after meta-analyses, none of the CpGs survived multiple test 
adjustment. Thus, our study does not find evidence for DNA methylation changes in relation to 
inhaled asthma treatment, although changes through other epigenetic mechanisms cannot be ruled 
out. Our results are based on an observational study and hence do not produce intention-to-treat 
results. There are some limitations: firstly, we could not completely adjust for severity of asthma as 
the severity is reflected in the medication mode itself. Secondly, in the 8-year follow-up we did not 
enquire about systemic steroid use and hence there may be subjects that have used systemic 
corticosteroids in the “any medication” group. Thirdly, heterogeneity between the BAMSE and 
STOPPA cohorts unlikely explains the lack of replication as both cohorts are from areas with similar 
lifestyle factors, ethnic background and sensitization patterns, although more mothers smoked 
during pregnancy in BAMSE and more parents in STOPPA had asthma, hay fever or allergies.  
 
Furthermore, we explored potential treatment–methylation associations using a candidate gene 
approach. We selected CpGs that were found robustly associated with asthma (per se) in the large 
study by Xu et al [3], where the authors did not specifically investigate potential influence from 
medication. We found a handful nominally associated CpGs with increased methylation in peripheral 
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blood cells, whereas for asthma, Xu et al reported consistently lower methylation levels. However, 
none survived multiple test adjustment in our study.   
 
There are well-known side effects from long-term systemic corticosteroid treatment, and the study 
by Wan et al found DNA methylation differences in COPD patients associated with systemic steroid 
use [4]. By exploring the top CpGs from Wan et al, we found no significant methylation differences in 
children and adolescents with asthma associated with inhaled corticosteroid treatment. However, it 
should be noted that Wan et al studied adult COPD patients and we included children and 
adolescents with asthma in our study. 
 
In conclusion, we found no evidence that inhaled corticosteroids or other asthma medications affect 
peripheral blood cell DNA methylation levels to any major extent, although smaller effects cannot be 
excluded.  
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